Chronic Graft versus Host Disease

Common Name(s)

Chronic Graft versus Host Disease

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Graft versus Host Disease" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Graft versus Host Disease" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Chronic Graft versus Host Disease" returned 390 free, full-text research articles on human participants. First 3 results:

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.
 

Author(s): Nicolaus Kröger, Carlos Solano, Christine Wolschke, Giuseppe Bandini, Francesca Patriarca, Massimo Pini, Arnon Nagler, Carmine Selleri, Antonio Risitano, Giuseppe Messina, Wolfgang Bethge, Jaime Pérez de Oteiza, Rafael Duarte, Angelo Michele Carella, Michele Cimminiello, Stefano Guidi, Jürgen Finke, Nicola Mordini, Christelle Ferra, Jorge Sierra, Domenico Russo, Mario Petrini, Giuseppe Milone, Fabio Benedetti, Marion Heinzelmann, Domenico Pastore, Manuel Jurado, Elisabetta Terruzzi, Franco Narni, Andreas Völp, Francis Ayuk, Tapani Ruutu, Francesca Bonifazi

Journal: N. Engl. J. Med.. 2016 Jan;374(1):43-53.

 

Chronic graft-versus-host disease (GVHD) is the leading cause of later illness and death after allogeneic hematopoietic stem-cell transplantation. We hypothesized that the inclusion of antihuman T-lymphocyte immune globulin (ATG) in a myeloablative conditioning regimen for patients ...

Last Updated: 7 Jan 2016

Go To URL
Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.
 

Author(s): Joseph Pidala, Jongphil Kim, Melissa Alsina, Ernesto Ayala, Brian C Betts, Hugo F Fernandez, Teresa Field, Heather Jim, Mohamed A Kharfan-Dabaja, Frederick L Locke, Asmita Mishra, Taiga Nishihori, Leonel Ochoa-Bayona, Lia Perez, Marcie Riches, Claudio Anasetti

Journal: Haematologica. 2015 Jul;100(7):970-7.

 

Effective pharmacological strategies employed in allogeneic hematopoietic cell transplantation should prevent serious chronic graft-versus-host disease and facilitate donor-recipient immune tolerance. Based on demonstrated pro-tolerogenic activity, sirolimus (rapamycin) is an agent ...

Last Updated: 1 Jul 2015

Go To URL
Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease.
 

Author(s): Jeanne Palmer, Xiaoyu Chai, Paul J Martin, Daniel Weisdorf, Yoshihiro Inamoto, Joseph Pidala, Madan Jagasia, Steven Pavletic, Corey Cutler, Georgia Vogelsang, Sally Arai, Mary E D Flowers, Stephanie J Lee

Journal: Haematologica. 2015 May;100(5):690-5.

 

Failure-free survival, defined as the absence of relapse, non-relapse mortality or addition of another systemic therapy, has been proposed as a potential endpoint for clinical trials, but its use has only been reported for single-center studies. We measured failure-free survival in ...

Last Updated: 6 May 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Chronic Graft versus Host Disease" returned 43 free, full-text review articles on human participants. First 3 results:

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.
 

Author(s): Sophie Paczesny, Frances T Hakim, Joseph Pidala, Kenneth R Cooke, Julia Lathrop, Linda M Griffith, John Hansen, Madan Jagasia, David Miklos, Steven Pavletic, Robertson Parkman, Estelle Russek-Cohen, Mary E D Flowers, Stephanie Lee, Paul Martin, Georgia Vogelsang, Marc Walton, Kirk R Schultz

Journal: Biol. Blood Marrow Transplant.. 2015 May;21(5):780-92.

 

Biology-based markers to confirm or aid in the diagnosis or prognosis of chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation or monitor its progression are critically needed to facilitate evaluation of new therapies. Biomarkers have been defined ...

Last Updated: 23 Apr 2015

Go To URL
B cells in chronic graft-versus-host disease.
 

Author(s): Stefanie Sarantopoulos, Bruce R Blazar, Corey Cutler, Jerome Ritz

Journal: Biol. Blood Marrow Transplant.. 2015 Jan;21(1):16-23.

 

Chronic graft-versus-host disease (cGVHD) continues to be a common complication of allogeneic hematopoietic stem cell transplantation. Unlike acute graft-versus-host disease, which is mediated almost entirely by donor T cells, the immune pathology of cGVHD is more complex and donor ...

Last Updated: 20 Dec 2014

Go To URL
How we treat chronic graft-versus-host disease.
 

Author(s): Mary E D Flowers, Paul J Martin

Journal: Blood. 2015 Jan;125(4):606-15.

 

Chronic graft-versus-host disease (GVHD) remains a common and potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation (HCT). The 2-year cumulative incidence of chronic GVHD requiring systemic treatment is ~30% to 40% by National Institutes of ...

Last Updated: 23 Jan 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
 

Status: Recruiting

Condition Summary: Chronic Graft Versus Host Disease; Chronic GVHD; Complications of Organ Transplant Stem Cells

 

Last Updated: 28 Jan 2016

Go to URL
An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease
 

Status: Recruiting

Condition Summary: Chronic Graft-versus-Host-Disease; Oral Mucosal Disease Due to Graft-versus-host Disease

 

Last Updated: 14 Oct 2014

Go to URL
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
 

Status: Recruiting

Condition Summary: Chronic Graft Versus Host Disease

 

Last Updated: 4 Feb 2016

Go to URL